Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload

Circulation. 2015 Apr 21;131(16):1435-47. doi: 10.1161/CIRCULATIONAHA.115.013894.

Authors

Gabriele G Schiattarella¹, Joseph A Hill²

Affiliations

¹ From Departments of Internal Medicine (Cardiology) (G.G.S., J.A.H.) and Molecular Biology (J.A.H.), University of Texas Southwestern Medical Center, Dallas, TX.
² From Departments of Internal Medicine (Cardiology) (G.G.S., J.A.H.) and Molecular Biology (J.A.H.), University of Texas Southwestern Medical Center, Dallas, TX. joseph.hill@utsouthwestern.edu.

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Cell Death
Endothelium, Vascular / pathology
Fibrosis
Gene Expression Regulation
Heart Conduction System / physiopathology
Histone Deacetylase Inhibitors / therapeutic use
Humans
Hypertension / complications
Hypertension / drug therapy
Hypertrophy, Left Ventricular / physiopathology
Hypertrophy, Left Ventricular / prevention & control*
Macrophages / metabolism
Myocytes, Cardiac / metabolism
Myocytes, Cardiac / pathology*
Ventricular Remodeling

Substances

Histone Deacetylase Inhibitors

Grants and funding